-
Lainate, Italy ? 2 April 2012 ? Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that it has signed a license agreement with a leading U.S. public pharmaceutical company granting it exclusive world-wide rights for the development and commercialization of Cosmo?s new chemical entity CB-03-01, an investigational anti-androgen drug targeted at certain topical skin applications. The license agreement provides for the payment of $25 million up-front, regulatory and commercial milestones and royalties on sales averaging those of other commercial transactions.Mauro Ajani, CEO of Cosmo Pharmaceuticals, commented: ?I am very proud of this agreement because we have partnered with one of the world?s leading specialty pharmaceutical companies. This is a very important next step in pursuing approval for this product.?